Inify Laboratories - mandatory notification of trade

29 Aug 2025 11:56 CEST

Stockholm, Sweden, August 29, 2025; Inify Laboratories AB (publ.) has been
notified that the following transactions have been completed by a primary
insider in Inify; Martin Ingvar, board member and primary insider in Inify, has
acquired 9,500 shares in Inify at an average price of SEK 5.50 per share on
August 28th. After the transaction, Ingvar holds 186,063 shares.

This information is subject to the disclosure requirements pursuant to the EU
Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the
Norwegian Securities Trading Act.

For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com.

###

About Inify Laboratories

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardized and AI-
supported workflow to optimize quality and response times, initially within
prostate.The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to
sample preparation, to reporting by a pathologist. The report is assisted by our
own AI, proven in clinical studies to have world-leading accuracy. The complete
workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off
fromContextVision (https://www.contextvision.com/), with 40 years of experience
within digital imaging for medical applications. Its' share is listed onEuronext
Growth Oslo under the ticker
INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).

More information:
Access the news on Oslo Bors NewsWeb site

654251_KvittoA003R844_12025_08_28_Finansinspektionen.pdf
654251_Mandatory_notification_of_trade_2025_08_29.pdf